During the past decade, Murmansk Regional Clinical Hospital named after P.A. Bayandin conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 2 clinical trials were completed, i.e. on average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Murmansk Regional Clinical Hospital named after P.A. Bayandin" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Biocad" with 2 trials sponsored, "Merck Sharp & Dohme LLC" with 2 trials sponsored, "Supergene, LLC" with 2 trials sponsored and "Boehringer Ingelheim" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Murmansk Regional Clinical Hospital named after P.A. Bayandin" #1 collaborator was "Astellas Pharma Global Development, Inc." with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Seagen Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Murmansk Regional Clinical Hospital named after P.A. Bayandin" are "Cervical Cancer" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Urinary Bladder Cancer, Muscle-invasive" (2 trials), "Cervical Cancer Metastatic" (1 trials) and "Cervical Cancer Recurrent" (1 trials). Many other conditions were trialed in "Murmansk Regional Clinical Hospital named after P.A. Bayandin" in a lesser frequency.

Most popular intervention types in "Murmansk Regional Clinical Hospital named after P.A. Bayandin" are "Drug" (12 trials), "Biological" (2 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Atezolizumab" (3 trials), "Cisplatin" (3 trials), "Pembrolizumab" (3 trials) and "BCD-100" (2 trials). Other intervention names were less common.

The vast majority of trials in "Murmansk Regional Clinical Hospital named after P.A. Bayandin" are 11 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Murmansk Regional Clinical Hospital named after P.A. Bayandin". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Murmansk Regional Clinical Hospital named after P.A. Bayandin, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Murmansk Regional Clinical Hospital named after P.A. Bayandin, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".